These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30526126)

  • 1. The 5th virus-like particle and nano-particle vaccines (VLPNPV) conference.
    Engeroff P; Bachmann MF
    Expert Rev Vaccines; 2019 Jan; 18(1):1-3. PubMed ID: 30526126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with nanoparticles combined with micro-adjuvants protects against cancer.
    Mohsen MO; Heath MD; Cabral-Miranda G; Lipp C; Zeltins A; Sande M; Stein JV; Riether C; Roesti E; Zha L; Engeroff P; El-Turabi A; Kundig TM; Vogel M; Skinner MA; Speiser DE; Knuth A; Kramer MF; Bachmann MF
    J Immunother Cancer; 2019 Apr; 7(1):114. PubMed ID: 31027511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Virus-like particle vaccines: immunology and formulation for clinical translation.
    Donaldson B; Lateef Z; Walker GF; Young SL; Ward VK
    Expert Rev Vaccines; 2018 Sep; 17(9):833-849. PubMed ID: 30173619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meeting report VLPNPV: Session 3: Immune responses.
    Morrison TG
    Hum Vaccin Immunother; 2014; 10(10):3064-7. PubMed ID: 25529229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering virus-like particles as vaccine platforms.
    Frietze KM; Peabody DS; Chackerian B
    Curr Opin Virol; 2016 Jun; 18():44-9. PubMed ID: 27039982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivering adjuvants and antigens in separate nanoparticles eliminates the need of physical linkage for effective vaccination.
    Mohsen MO; Gomes AC; Cabral-Miranda G; Krueger CC; Leoratti FM; Stein JV; Bachmann MF
    J Control Release; 2017 Apr; 251():92-100. PubMed ID: 28257987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant formulations for virus-like particle (VLP) based vaccines.
    Cimica V; Galarza JM
    Clin Immunol; 2017 Oct; 183():99-108. PubMed ID: 28780375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Envelope-Modified Tetravalent Dengue Virus-Like-Particle Vaccine Has Implications for Flavivirus Vaccine Design.
    Urakami A; Ngwe Tun MM; Moi ML; Sakurai A; Ishikawa M; Kuno S; Ueno R; Morita K; Akahata W
    J Virol; 2017 Dec; 91(23):. PubMed ID: 28956764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Virus-Like Particles as an Instrument of Vaccine Production].
    Syomin BV; Ilyin YV
    Mol Biol (Mosk); 2019; 53(3):367-379. PubMed ID: 31184601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2.
    Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B
    Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.
    Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL
    J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Virus-Like-Particle Vaccine and Reporter Assay for Zika Virus.
    Garg H; Sedano M; Plata G; Punke EB; Joshi A
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28794019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virus-Like Particles as an Immunogenic Platform for Cancer Vaccines.
    Caldeira JC; Perrine M; Pericle F; Cavallo F
    Viruses; 2020 Apr; 12(5):. PubMed ID: 32349216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
    Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meeting report VLPNPV: Sessions 1 and 2: Plenary.
    Sainsbury F
    Hum Vaccin Immunother; 2014; 10(10):3060-3. PubMed ID: 25485812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meeting report VLPNPV: Session 5: Plant based technology.
    Meador LR; Mor TS
    Hum Vaccin Immunother; 2014; 10(10):3068-73. PubMed ID: 25581535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meeting report VLPNPV: Session 10: Virus-like particle and nano-particle vaccines.
    Effio CL; Hubbuch J
    Hum Vaccin Immunother; 2014; 10(10):3080-2. PubMed ID: 25458914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Immunogenicity of a Potyvirus-Like Particle as an Adjuvant of a Synthetic Peptide.
    Cárdenas-Vargas A; Elizondo-Quiroga D; Gutierrez-Ortega A; Charles-Niño C; Pedroza-Roldán C
    Viral Immunol; 2016 Dec; 29(10):557-564. PubMed ID: 27834623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced Influenza Virus-Like Particle Vaccination with a Structurally Optimized RIG-I Agonist as Adjuvant.
    Beljanski V; Chiang C; Kirchenbaum GA; Olagnier D; Bloom CE; Wong T; Haddad EK; Trautmann L; Ross TM; Hiscott J
    J Virol; 2015 Oct; 89(20):10612-24. PubMed ID: 26269188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.